Immuron(NASDAQ:IMRN) $Immuron(IMRN)$ 今天疯了,我从250%开始看,然后没买,后来到了差不多800%啊。//@肖恩大侠:回复@chuminhua:1,现在市值不到收购价格的一半,且收购价格的构成里还有另外的额外潜在1600万美元;2,还是抗感染领域【疫情以来,抗病毒抗感染都还比较热门,包括国内以前那个micurx,也是一级市场比较被看好】;3,目前的市值也就1亿人民币的体量;
有点吸引力,就是现在交易活跃度还没有,或有被炒作可能的。于是买个底仓,并持续关注,等待收货。



看了报道,为了接受现在这个MLNT, 之前TTPH没同意ACRX的收购,还赔了ACRX 177.8万美元。详细报道请看:网页链接


部分内容copy 如下,through a tender offer, for an aggregate of $39.0 million in cash, plus an additional $16.0 million in cash potentially payable under contingent value rights (“CVRs”) to be issued in the proposed acquisition.
Under the terms of the definitive merger agreement, the upfront cash consideration in the transaction will be as follows: (i) $1.79 per share of Tetraphase common stock (including common stock underlying restricted stock units, performance-based stock units and pre-funded warrants), (ii) $2.47 per share of Tetraphase common stock underlying the common stock warrants issued by the Company in 2019, and (iii) $2.47 per share of Tetraphase common stock underlying the common stock warrants issued by the Company in 2020.Tetraphase equityholders would also be entitled to receive, for each share of Tetraphase common stock, one non-tradeable CVR, the holders of which will be entitled to receive payments of up to an additional $16.0 million in the aggregate upon the achievement of net sales of XERAVA™ in the United States of at least (i) $20 million during 2021, (ii) $35 million during any year ending on or before December 31, 2024 and (iii) $55 million during any year ending on or before December 31, 2024.
雪球转发:0回复:3喜欢:0
引用:
6月4日,生物制药公司Tetraphase Pharmaceuticals$Tetraphase制药(TTPH)$ 是一家致力于将其新型四环素XERAVA™商业化以治疗严重和威胁生命的感染的生物制药公司,宣布已与Melinta Therapeutics 签订最终合并协议,据此,Melinta将通过要约收购方式收购Tetraphase,以总计3,900万美元的现金,以及...

全部评论

肖恩大侠2020-07-05 00:03

拍一拍 加油发现下一个

桃乐丝萌萌哒2020-07-04 17:09

别说了 说多都是泪 我关注它的时候才2刀我也没买。。没上车

chuminhua2020-06-10 23:38

暴涨啊